PMID- 24996830
OWN - NLM
STAT- MEDLINE
DCOM- 20150525
LR  - 20211021
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 22
IP  - 12
DP  - 2014 Dec
TI  - Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy 
      for castration-resistant prostate cancer.
PG  - 3219-26
LID - 10.1007/s00520-014-2328-7 [doi]
AB  - PURPOSE: Docetaxel is a standard therapy for patients with castration-resistant 
      prostate cancer (CRPC). However, docetaxel-associated adverse events (AEs) such 
      as febrile neutropenia (FN) can impair quality of life and may become 
      life-threatening. In this study, we clarified the AEs and risk factors associated 
      with FN in clinical settings. METHODS: This study included 37 Japanese patients 
      with CRPC who were treated with 70-75 mg/m(2) docetaxel and 10 mg prednisone 
      every 3 or 4 weeks between 2008 and 2012. AEs, risk factors for FN, and the 
      prognostic significance of several clinicopathological factors were analyzed. 
      RESULTS: Hematological AEs of >/=grade 3 included neutrocytopenia in 36 patients 
      (97.3 %), leukopenia in 24 patients (64.9 %), lymphopenia in 10 patients (27.0 
      %), and FN in 4 patients (10.8 %). In addition, severe non-hematological AEs 
      included colonic perforation, interstitial pneumonia, and acute respiratory 
      distress syndrome in 1 patient each. Severe lymphopenia was positively associated 
      with the incidence of FN. Low serum albumin and low lymphocyte count were 
      identified as possible pre-treatment risk factors, while severe lymphopenia was 
      identified as a post-treatment risk factor. CONCLUSIONS: Non-hematological AEs as 
      well as substantial hematological AEs were recognized in the Japanese population 
      treated with docetaxel chemotherapy against CRPC. Pre- and post-treatment 
      lymphopenia and pre-treatment serum albumin should be considered in order to 
      minimize the risk of FN when selecting patients with prostate cancer for 
      docetaxel therapy, and when considering dose modifications, and the prophylactic 
      use of granulocyte colony-stimulating factor.
FAU - Shiota, Masaki
AU  - Shiota M
AD  - Department of Urology Graduate School of Medical Sciences, Kyushu University, 
      3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
FAU - Yokomizo, Akira
AU  - Yokomizo A
FAU - Takeuchi, Ario
AU  - Takeuchi A
FAU - Kiyoshima, Keijiro
AU  - Kiyoshima K
FAU - Inokuchi, Junichi
AU  - Inokuchi J
FAU - Tatsugami, Katsunori
AU  - Tatsugami K
FAU - Naito, Seiji
AU  - Naito S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140705
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Taxoids)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 15H5577CQD (Docetaxel)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - *Adenocarcinoma/epidemiology/pathology/therapy
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/adverse effects
MH  - *Chemotherapy-Induced Febrile Neutropenia/epidemiology/physiopathology/prevention 
      & control
MH  - Docetaxel
MH  - Drug Monitoring
MH  - Granulocyte Colony-Stimulating Factor/therapeutic use
MH  - Humans
MH  - Incidence
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Prednisone/therapeutic use
MH  - Prognosis
MH  - *Prostatic Neoplasms, Castration-Resistant/epidemiology/pathology/therapy
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - *Taxoids/administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2014/07/06 06:00
MHDA- 2015/05/26 06:00
CRDT- 2014/07/06 06:00
PHST- 2013/11/23 00:00 [received]
PHST- 2014/06/16 00:00 [accepted]
PHST- 2014/07/06 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/05/26 06:00 [medline]
AID - 10.1007/s00520-014-2328-7 [doi]
PST - ppublish
SO  - Support Care Cancer. 2014 Dec;22(12):3219-26. doi: 10.1007/s00520-014-2328-7. 
      Epub 2014 Jul 5.